Literature DB >> 10931104

The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism.

S Soule1, C Van Zyl Smit, G Parolis, S Attenborough, D Peter, S Kinvig, T Kinvig, E Coetzer.   

Abstract

OBJECTIVE: The 1 microgram ACTH stimulation test has been advocated as a sensitive indicator of the integrity of the hypothalamic-pituitary-adrenal axis in patients with suspected hypopituitarism. The aim of our study was to define the normal response to 1 microgram ACTH stimulation in a control population and to study the sensitivity and specificity of the test in a group of patients with suspected pituitary disease.
DESIGN: A prospective analysis of the performance of the 1 microgram ACTH stimulation test in a group of patients with pituitary disease. PATIENTS: The cortisol response to 1 microgram ACTH was evaluated in 21 normal subjects and 65 patients with pituitary disease. The patients with pituitary disease were divided into two groups according to the 11-deoxycortisol response to overnight metyrapone: normal (11-deoxycortisol > 200 nmol/l) and subnormal ACTH secretory status (11-deoxycortisol < 200 nmol/l). MEASUREMENTS: In both controls and patients, blood was sampled for cortisol at - 15, 0, + 20, + 30, + 40 and + 60 minutes after intravenous administration of 1 microgram synthetic ACTH (Synacthen(R)). The overnight metyrapone test was performed only in the subjects with pituitary disease. Metyrapone (30 mg/kg) was administered orally at 2300 h and blood was sampled at 0830 h the following morning for 11-deoxycortisol.
RESULTS: The 65 patients with pituitary disease were categorized according to the 11-deoxycortisol response to metyrapone as follows: 53 normal (11-deoxycortisol > 200 nmol/l) and 12 subnormal (< 200 nmol/l). The 12 patients who failed the metyrapone test had a significantly impaired cortisol response to low dose ACTH stimulation at all time points when compared with both the control group and the pituitary patients with a normal response to metyrapone (P < 0.001). Comparing the pituitary patients who had a normal response to metyrapone and the control subjects, there was no significant difference in the cortisol response to ACTH (P > 0.05). The minimum cortisol response at 30 minutes in the 21 control subjects was 414 nmol/l and this was defined as the minimum normal cortisol response to 1 microg ACTH. Using this criterion, six of the 12 patients with a subnormal response to metyrapone had a normal cortisol response to low dose ACTH stimulation. Empirically increasing the cortisol cut-off to 600 nmol/l increased the sensitivity of the low dose ACTH test to 83%, although the specificity was reduced from 100% to only 58%.
CONCLUSIONS: The normal cortisol response to low dose ACTH stimulation in 50% of the patients with ACTH deficiency proven on metyrapone testing suggests that the 1 microgram ACTH stimulation test, like the 250 microgram-test, lacks sensitivity for the diagnosis of ACTH deficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931104     DOI: 10.1046/j.1365-2265.2000.01057.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Total and free cortisol levels during 1 μg, 25 μg, and 250 μg cosyntropin stimulation tests compared to insulin tolerance test: results of a randomized, prospective, pilot study.

Authors:  Seenia Peechakara; James Bena; Nigel J Clarke; Michael J McPhaul; Richard E Reitz; Robert J Weil; Pablo Recinos; Laurence Kennedy; Amir H Hamrahian
Journal:  Endocrine       Date:  2017-07-20       Impact factor: 3.633

2.  Characterization of the serum and salivary cortisol response to the intravenous 250 µg ACTH1-24 stimulation test.

Authors:  Brendan J Nolan; Jane Sorbello; Nigel Brown; Goce Dimeski; Warrick J Inder
Journal:  Endocrine       Date:  2018-01-03       Impact factor: 3.633

3.  Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test.

Authors:  L Pescollderungg; G Radetti; E Gottardi; D G Peroni; A Pietrobelli; A L Boner
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

4.  Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease.

Authors:  G Aimaretti; C Baffoni; L Di Vito; S Grottoli; D Gaia; V Gasco; R Giordano; Z Zadik; F Camanni; E Ghigo; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

Review 5.  Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS).

Authors:  Ioannis Karamouzis; Loredana Pagano; Flavia Prodam; Chiara Mele; Marco Zavattaro; Arianna Busti; Paolo Marzullo; Gianluca Aimaretti
Journal:  Endocrine       Date:  2015-11-16       Impact factor: 3.633

Review 6.  Secondary hypoadrenalism.

Authors:  Giuseppe Reimondo; Silvia Bovio; Barbara Allasino; Massimo Terzolo; Alberto Angeli
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

7.  CD4 count as a predictor of adrenocortical insufficiency in persons with human immunodeficiency virus infection: How useful?

Authors:  Ifedayo A Odeniyi; Olufemi A Fasanmade; Michael O Ajala; Augustin E Ohwovoriole
Journal:  Indian J Endocrinol Metab       Date:  2013-11

8.  Evaluation of the hypothalamic-pituitary-adrenal axis and its relationship with central respiratory dysfunction in children with Prader-Willi syndrome.

Authors:  Veronique Beauloye; K Dhondt; W Buysse; A Nyakasane; F Zech; J De Schepper; S Van Aken; K De Waele; M Craen; I Gies; I Francois; D Beckers; A Desloovere; G Francois; M Cools
Journal:  Orphanet J Rare Dis       Date:  2015-09-02       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.